10-Q 1 dlhc-20221231.htm 10-Q dlhc-20221231
0000785557false2023Q1September 3000007855572022-10-012022-12-3100007855572023-02-08xbrli:sharesiso4217:USD00007855572021-10-012021-12-310000785557us-gaap:RetainedEarningsMember2022-10-012022-12-31iso4217:USDxbrli:shares0000785557dlhc:GroveResourceSolutionsLLCMember2021-10-012021-12-310000785557dlhc:GroveResourceSolutionsLLCMember2022-10-012022-12-3100007855572022-12-3100007855572022-09-3000007855572021-09-3000007855572021-12-310000785557us-gaap:CommonStockMember2022-09-300000785557us-gaap:AdditionalPaidInCapitalMember2022-09-300000785557us-gaap:RetainedEarningsMember2022-09-300000785557us-gaap:CommonStockMember2022-10-012022-12-310000785557us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000785557us-gaap:CommonStockMember2022-12-310000785557us-gaap:AdditionalPaidInCapitalMember2022-12-310000785557us-gaap:RetainedEarningsMember2022-12-310000785557us-gaap:CommonStockMember2021-09-300000785557us-gaap:AdditionalPaidInCapitalMember2021-09-300000785557us-gaap:RetainedEarningsMember2021-09-300000785557us-gaap:AdditionalPaidInCapitalMember2021-10-012021-12-310000785557us-gaap:CommonStockMember2021-10-012021-12-310000785557us-gaap:RetainedEarningsMember2021-10-012021-12-310000785557us-gaap:CommonStockMember2021-12-310000785557us-gaap:AdditionalPaidInCapitalMember2021-12-310000785557us-gaap:RetainedEarningsMember2021-12-310000785557srt:MinimumMember2022-10-012022-12-310000785557srt:MaximumMember2022-10-012022-12-310000785557us-gaap:EmployeeStockOptionMember2022-12-310000785557us-gaap:EmployeeStockOptionMember2022-10-012022-12-310000785557dlhc:GroveResourceSolutionsLLCMember2022-12-08xbrli:pure0000785557dlhc:GroveResourceSolutionsLLCMember2022-12-082022-12-080000785557dlhc:GroveResourceSolutionsLLCMemberus-gaap:CommonStockMember2022-12-082022-12-080000785557dlhc:DepartmentOfVeteransAffairsMember2022-10-012022-12-310000785557dlhc:DepartmentOfVeteransAffairsMember2021-10-012021-12-310000785557dlhc:DepartmentofHealthandHumanServicesMember2022-10-012022-12-310000785557dlhc:DepartmentofHealthandHumanServicesMember2021-10-012021-12-310000785557dlhc:DepartmentOfDefenseMember2022-10-012022-12-310000785557dlhc:DepartmentOfDefenseMember2021-10-012021-12-310000785557dlhc:DepartmentOfHomelandSecurityMember2022-10-012022-12-310000785557dlhc:DepartmentOfHomelandSecurityMember2021-10-012021-12-310000785557dlhc:OtherCustomersMember2022-10-012022-12-310000785557dlhc:OtherCustomersMember2021-10-012021-12-310000785557us-gaap:TimeAndMaterialsContractMember2022-10-012022-12-310000785557us-gaap:TimeAndMaterialsContractMember2021-10-012021-12-310000785557dlhc:CostPlusFixedFeeContractMember2022-10-012022-12-310000785557dlhc:CostPlusFixedFeeContractMember2021-10-012021-12-310000785557us-gaap:FixedPriceContractMember2022-10-012022-12-310000785557us-gaap:FixedPriceContractMember2021-10-012021-12-310000785557us-gaap:SalesChannelDirectlyToConsumerMember2022-10-012022-12-310000785557us-gaap:SalesChannelDirectlyToConsumerMember2021-10-012021-12-310000785557us-gaap:SalesChannelThroughIntermediaryMember2022-10-012022-12-310000785557us-gaap:SalesChannelThroughIntermediaryMember2021-10-012021-12-31dlhc:subleasedlhc:sublease_option0000785557us-gaap:CustomerRelationshipsMember2022-12-310000785557us-gaap:CustomerRelationshipsMember2022-09-300000785557us-gaap:NoncompeteAgreementsMember2022-12-310000785557us-gaap:NoncompeteAgreementsMember2022-09-300000785557us-gaap:TradeNamesMember2022-12-310000785557us-gaap:TradeNamesMember2022-09-300000785557dlhc:SecuredRevolvingLineOfCreditMember2022-12-310000785557dlhc:SecuredRevolvingLineOfCreditMember2022-09-300000785557us-gaap:SecuredDebtMember2022-12-310000785557us-gaap:SecuredDebtMember2022-09-300000785557us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredDebtMember2022-12-310000785557us-gaap:MediumTermNotesMemberus-gaap:SecuredDebtMember2022-12-310000785557us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredDebtMember2022-12-310000785557us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:MediumTermNotesMemberus-gaap:SecuredDebtMember2022-12-310000785557us-gaap:MediumTermNotesMemberus-gaap:SecuredDebtMember2022-10-012022-12-310000785557us-gaap:MediumTermNotesMembersrt:MaximumMemberus-gaap:SecuredDebtMember2022-10-012022-12-310000785557dlhc:ExcessCashFlowsGreaterThanOrEqualto2.50Memberus-gaap:MediumTermNotesMemberus-gaap:SecuredDebtMember2022-10-012022-12-310000785557us-gaap:MediumTermNotesMemberus-gaap:SecuredDebtMemberdlhc:ExcessCashFlowsLessThan250Member2022-10-012022-12-310000785557us-gaap:MediumTermNotesMembersrt:MaximumMemberus-gaap:SecuredDebtMemberdlhc:ExcessCashFlowsLessThan250Member2022-10-012022-12-310000785557us-gaap:MediumTermNotesMemberdlhc:ExcessCashFlowsEqualto1.50Memberus-gaap:SecuredDebtMember2022-10-012022-12-310000785557us-gaap:MediumTermNotesMemberdlhc:ExcessCashFlowsLessThan1.50Memberus-gaap:SecuredDebtMember2022-10-012022-12-310000785557us-gaap:InterestRateSwapMember2022-12-310000785557us-gaap:InterestRateSwapMember2022-10-012022-12-310000785557us-gaap:StandbyLettersOfCreditMemberus-gaap:SecuredDebtMember2022-09-300000785557us-gaap:SellingGeneralAndAdministrativeExpensesMemberdlhc:DLHEmployeesMember2022-10-012022-12-310000785557us-gaap:SellingGeneralAndAdministrativeExpensesMemberdlhc:DLHEmployeesMember2021-10-012021-12-310000785557us-gaap:SellingGeneralAndAdministrativeExpensesMemberdlhc:NonemployeeDirectorsMember2022-10-012022-12-310000785557us-gaap:SellingGeneralAndAdministrativeExpensesMemberdlhc:NonemployeeDirectorsMember2021-10-012021-12-310000785557us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-10-012022-12-310000785557us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-10-012021-12-310000785557dlhc:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-10-012022-12-310000785557dlhc:NamedExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2021-10-012021-12-310000785557us-gaap:RestrictedStockUnitsRSUMemberdlhc:NonemployeeDirectorsMember2022-10-012022-12-310000785557us-gaap:RestrictedStockUnitsRSUMemberdlhc:NonemployeeDirectorsMember2021-10-012021-12-310000785557dlhc:DLHEmployeesMember2022-12-310000785557dlhc:DLHEmployeesMember2021-12-310000785557dlhc:NonemployeeDirectorsMember2022-12-310000785557dlhc:NonemployeeDirectorsMember2021-12-310000785557dlhc:DLHEmployeesMember2022-10-012022-12-3100007855572020-10-012021-09-3000007855572021-10-012022-06-300000785557dlhc:FacilityLeasesMember2022-12-310000785557dlhc:EquipmentLeasesMember2022-12-31

Washington, D.C. 20549
For the quarterly period ended December 31, 2022
For the transition period from                        to
Commission File No. 0-18492
(Exact name of registrant as specified in its charter)
New Jersey 22-1899798
(State or other jurisdiction of
 incorporation or organization)
(I.R.S. Employer
Identification No.)

3565 Piedmont Road,Building 3, Suite 700 30305
Atlanta, Georgia
(Zip code)
(Address of principal executive offices)
(770) 554-3545
(Registrant’s telephone number, including area code)

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockDLHCNasdaqCapital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes      No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes    No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
Non-accelerated filer Smaller Reporting Company
 Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No ý
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 13,756,969 shares of Common Stock, par value $0.001 per share, were outstanding as of February 8, 2023.

Table of Contents
Page No.



(In thousands, except per share amounts)
Three Months Ended
 December 31,
Revenue$72,738 $152,801 
Cost of operations:
Contract costs57,256 132,686 
General and administrative costs7,424 6,911 
Corporate development costs1,735  
Depreciation and amortization2,402 1,985 
Total operating costs68,817 141,582 
Income from operations3,921 11,219 
Interest expense1,830 672 
Income before provision for income taxes2,091 10,547 
Provision for income taxes544 2,743 
Net income$1,547 $7,804 
Net income per share - basic$0.12 $0.61 
Net income per share - diluted$0.11 $0.55 
Weighted average common stock outstanding
Basic13,306 12,749 
Diluted14,276 14,295 
The accompanying notes are an integral part of these consolidated financial statements.

(In thousands, except par value of shares) 
December 31,
September 30,
Current assets:  
Cash$1,364 $228 
Accounts receivable65,178 40,496 
Other current assets3,249 2,878 
Total current assets69,791 43,602 
Equipment and improvements, net1,875 1,704 
Operating lease right-of-use assets19,595 16,851 
Goodwill139,277 65,643 
Intangible assets, net136,729 40,884 
Other long-term assets61 328 
Total assets$367,328 $169,012 
Current liabilities:  
Operating lease liabilities - current$3,379 $2,235 
Accrued payroll16,540 9,444 
Debt obligations - current, net of deferred financing costs28,505  
Accounts payable and accrued liabilities32,711 26,862 
Total current liabilities81,135 38,541 
Long-term liabilities:
Deferred taxes, net 1,521 1,534 
Operating lease liabilities - long-term18,221 16,461 
Debt obligations - long-term, net of deferred financing costs165,942 20,416 
Total long-term liabilities185,684 38,411 
Total liabilities266,819 76,952 
Shareholders' equity:
Common stock, $0.001 par value; 40,000 shares authorized; 13,757 and 13,047 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively
14 13 
Additional paid-in capital97,958 91,057 
Retained earnings2,537 990 
Total shareholders’ equity100,509 92,060 
Total liabilities and shareholders' equity$367,328 $169,012 

The accompanying notes are an integral part of these consolidated financial statements.

(In thousands) 
Three Months Ended
December 31,
Operating activities  
Net income$1,547 $7,804 
Adjustments to reconcile net income to net cash provided by (used in) operating activities:  
Depreciation and amortization2,402 1,985 
Amortization of deferred financing costs charged to interest expense276 151 
Stock-based compensation expense552 500 
Deferred taxes, net(13) 
Changes in operating assets and liabilities  
Accounts receivable780 (13,396)
Other current assets994 (632)
Accrued payroll347 1,851 
Deferred revenue (12,125)
Accounts payable and accrued liabilities1,075 (2,335)
Other long-term assets and liabilities13 42 
Net cash provided by (used in) operating activities7,973 (16,155)
Investing activities  
Business acquisition, net of cash acquired(179,958) 
Purchase of equipment and improvements(384) 
Net cash used in investing activities(180,342) 
Financing activities  
Proceeds from debt obligations200,703 6,000 
Repayments of debt obligations(19,327)(9,875)
Payments of deferred financing costs(7,221) 
Proceeds from issuance of common stock upon exercise of options and warrants 200 
Payment of tax obligations resulting from net exercise of stock options(650) 
Net cash provided by (used in) financing activities173,505 (3,675)
Net change in cash1,136 (19,830)
Cash - beginning of period228 24,051 
Cash - end of period$1,364 $4,221 
Supplemental disclosure of cash flow information  
Cash paid during the period for interest$339 $513 
Cash paid during the period for income taxes$5 $ 
Supplemental disclosure of non-cash activity
Common stock surrendered for the exercise of stock options$238 $ 

The accompanying notes are an integral part of these consolidated financial statements.

(In thousands) 
Common StockAdditional
Retained EarningsTotal Shareholders' Equity
Three Months Ended December 31, 2022
Balance at September 30, 202213,047 $13 $91,057 $990 $92,060 
Issuance of common stock in business combination527 1 6,999 — 7,000 
Expense related to director restricted stock units— — 180 — 180 
Expense related to employee stock-based compensation— — 372 — 372 
Exercise of stock options250 —  —  
Common stock surrendered for the exercise of stock options(67)— (650)— (650)
Net income— — — 1,547 1,547 
Balance at December 31, 202213,757 $14 $97,958 $2,537 $100,509 

Common StockAdditional
Total Shareholders' Equity
Three Months Ended December 31, 2021
Balance at September 30, 202112,714 $13 $87,893 $(22,298)$65,608 
Expense related to director restricted stock units— — 162 — 162 
Expense related to employee stock-based compensation— — 338 — 338 
Exercise of stock warrants54 — 200 — 200 
Net income— — — 7,804 7,804 
Balance at December 31, 202112,768 $13 $88,593 $(14,494)$74,112 

The accompanying notes are an integral part of these consolidated financial statements.

December 31, 2022
1. Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements include the accounts of DLH Holdings Corp. and its wholly-owned subsidiaries (together with its subsidiaries, "DLH" or the "Company" and also referred to as "we," "us" and "our"). All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, these statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

In management's opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the period ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023 or any future period. Amounts as of and for the three months ended December 31, 2022 and December 31, 2021 are unaudited. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2022 filed with the Securities and Exchange Commission on December 5, 2022.

2. Significant Accounting Policies

Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. The most significant of these estimates and assumptions relate to estimating revenues and costs including overhead and its allocation, estimating progress toward the completion of performance obligations, assessing fair value of acquired assets and liabilities accounted for through business acquisitions, valuing and determining the amortization periods for long-lived intangible assets, interest rate swaps, stock-based compensation, right-of-use assets and leases liabilities, and loss development on workers' compensation claims. We evaluate these estimates and judgments on an ongoing basis and base our estimates on historical experience, current and expected future outcomes, third-party evaluations, and various other assumptions that we believe are reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities as well as identifying and assessing the accounting treatment with respect to commitments and contingencies. We revise material accounting estimates if changes occur, such as more experience is acquired, additional information is obtained, or there is new information on which an estimate was or can be based. Actual results could differ from those estimates.


The Company's revenues from contracts with customers are derived from offerings that include technology-enabled business process outsourcing, program management solutions, and public health research and analytics, substantially within the U.S. government and its agencies, and to a lesser extent, subcontractors. The Company has various types of contracts including time-and-materials contracts, cost-reimbursable contracts, and firm-fixed-price contracts.

We consider a contract with a customer to exist when there is a commitment by both parties (customer and Company), payment terms are determinable, there is commercial substance, and collectability is probably in accordance with Accounting Standards Codification ("ASC") No. 606, Revenue from Contracts with Customers ("Topic 606").

We recognize revenue over time when there is a continuous transfer of control to our customer as performance obligations are satisfied. For our U.S. government contracts, this continuous transfer of control to the customer is transferred over time and revenue is recognized based on the extent of progress toward completion of the performance obligation. We consider control to transfer when we have a right to payment. In some instances, the Company commences providing services prior to formal approval to begin work from the customer. The Company considers these factors, the risks associated with commencing work, and legal enforceability in determining whether a contract exists under Topic 606.

Contract modification can occur throughout the life of the contract and can affect the transaction price, extend the period of performance, adjust funding, or create new performance obligations. We review each modification to assess the impact of these

contract changes to determine if it should be treated as part of the original performance obligation or as a separate contract. Contract modifications impact performance obligations when the modification either creates new or changes the existing enforceable rights and obligations. The effect of a contract modification on the transaction price and our measure of progress for the performance obligation to which it relates is recognized as an adjustment to revenue and profit cumulatively. Furthermore, a significant change in one or more estimates could affect the profitability of our contracts. We recognize adjustments in estimated profit on contracts in the period identified.

For service contracts, we satisfy our performance obligations as services are rendered. We use cost-based input and time-based output methods to measure progress based on the contract type.
Time and material - We bill the customer per labor hour and per material, and revenue is recognized in the amount invoiced as the amount corresponds directly to the value of our performance to date. Revenue is recognized to the extent of billable rates times hours delivered plus materials and other reimbursable costs incurred.
Cost reimbursable - We record reimbursable costs as incurred, including an estimated share of the contractual fee earned.
Firm fixed price - We recognize revenue over time using a straight-line measure of progress or percentage of completion method whereby progress toward completion is based on a comparison of actual costs incurred to total estimated costs to be incurred over the contract terms.

Contract costs generally include direct costs such as labor, materials, subcontract costs, and indirect costs identifiable with or allocable to a specific contract. Costs are expensed as incurred and include an estimate of the contractual fees earned. Contract costs incurred for U.S. government contracts, including indirect costs, are subject to audit and adjustment by various government audit agencies. Historically, our adjustments have not been material.

Contract assets - Amounts are invoiced as work progresses in accordance with agreed-upon contractual terms. In part, revenue recognition occurs before we have the right to bill, resulting in contract assets. These contract assets are reported within Accounts receivable, net on our consolidated balance sheets and are invoiced in accordance with payment terms defined in each contract. Period end balances will vary from period to period due to agreed-upon contractual terms.

Contract liabilities - Amounts are a result of billings in excess of costs incurred or prepayment for services to be rendered.

Fair Value of Financial Instruments
The carrying amounts of the Company's cash and cash equivalents, accounts receivable, contract assets, contract liabilities, accrued expenses, and accounts payable approximate fair value due to the short-term nature of these instruments. The fair values of the Company's debt instruments approximate fair value because the underlying interest rates approximate market rates that the Company could obtain for similar instruments at the balance sheet dates.

Long-lived Assets

Our long-lived assets include equipment and improvements, intangible assets, right-of-use assets, and goodwill. The Company continues to review long-lived assets for possible impairment or loss of value at least annually, or more frequently upon the occurrence of an event or when circumstances indicate that a reporting unit's carrying amount is greater than its fair value.

Equipment and improvements are recorded at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful asset lives (3 to 7 years) and the shorter of the initial lease term or estimated useful life for leasehold improvements. Maintenance and repair costs are expensed as incurred. Intangible assets (other than goodwill) are originally recorded at fair value and are amortized on a straight-line basis over their estimated useful lives of 10 years. Maintenance and repair costs are expensed as incurred.

Right-of-use assets are measured at the present value of future minimum lease payments, including all probable renewals, plus lease payments made to the lessor before or at lease commencement and indirect costs paid, less incentives received. Our right-of-use assets include long-term leases for facilities and equipment and are amortized over their respective lease terms.


Lease Liabilities

The Company has leases for facilities and office equipment. Our lease liabilities are recognized as the present value of the future minimum lease payments over the lease term. Our lease payments consist of fixed and in-substance fixed amounts attributable to the use of the underlying asset over the lease term. Variable lease payments that do not depend on an index rate or are not in-substance fixed payments are excluded in the measurement of right-of-use assets and lease liabilities and are expensed in the period incurred. The incremental borrowing rate on our secured term loan is used in determining the present value of future minimum lease payments. Some of our lease agreements include options to extend the lease term or terminate the lease. These options are accounted for in our right-of-use assets and lease liabilities when it is reasonably certain that the Company will extend the lease term or terminate the lease. The Company does not have any finance leases.


The Company reviews goodwill for impairment on an annual basis and on a quarterly basis the company assesses the impact of any macroeconomic changes that may impact the business conditions to determine if these changes have any adverse impact to goodwill. Notwithstanding this evaluation, factors including non-renewal of a major contract or other substantial changes in business conditions could have a material adverse effect on the valuation of goodwill in future periods and the resulting charge could be material to future periods’ results of operations. The Company determined that no change in business conditions occurred which would have a material adverse effect on the valuation of goodwill.

Provision for Income Taxes

The Company accounts for income taxes in accordance with the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reflected on the consolidated balance sheets when it is determined that it is more likely than not that the asset will be realized. This guidance also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax asset will not be realized. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon the technical merits, it is more-likely-than-not that the position will be sustained upon examination. We had no uncertain tax positions at either December 31, 2022 or September 30, 2022. We report interest and penalties as a component of provision for income taxes. During the three months ended December 31, 2022 and December 31, 2021, we recognized no interest and no penalties related to income taxes.

Stock-based Compensation

The Company uses the fair value-based method for stock-based compensation. Options issued are designated as either an incentive stock option or a non-statutory stock option. No option may be granted with a term of more than 10 years from the date of grant. Option awards may depend on achievement of certain performance measures determined by the Compensation Committee of our Board. Shares issued upon option exercise are newly issued common shares. All awards to employees and non-employees are recorded at fair value on the date of the grant and expensed over the period of vesting. The Company uses a Monte Carlo method to estimate the fair value of each stock option at the date of grant. Any consideration paid by the option holders to purchase shares is credited to common stock.

Compensation Expense

Compensation expense for the portion of equity awards for which the requisite service has not been rendered is recognized as the requisite service is rendered. The compensation expense for that portion of awards has been based on the grant-date fair value of those awards as calculated for recognition purposes under applicable guidance. For options that vest based on the Company’s common stock achieving and maintaining defined market prices, the Company values the awards with a Monte Carlo method that utilizes various probability factors and other criterion in establishing fair value of the grant. The related compensation expense is recognized over the service period.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. We maintain cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Deposits held with financial institutions may exceed the $250,000 limit.


Accounts Receivable

Receivables include amounts billed and currently due from customers where the right to consideration is unconditional and amounts unbilled. Both billed and unbilled amounts are non-interest bearing, unsecured, and recognized at an estimated realizable value that includes costs and fees, and are generally expected to be billed and received within a single year. We evaluate our receivables on a quarterly basis and determine whether an allowance is appropriate based on specific collection issues. No allowance for doubtful accounts was deemed necessary at either December 31, 2022 or September 30, 2022.

Earnings Per Share

Basic earnings per share is calculated by dividing income available to common shareholders by the weighted average number of common stock outstanding and restricted stock grants that vested or are likely to vest during the period. Diluted earnings per share is calculated by dividing income available to common shareholders by the weighted average number of basic common shares outstanding, adjusted to reflect potentially dilutive securities. Diluted earnings per share is calculated using the treasury stock method.

Treasury Stock

The Company periodically purchases its own common stock that is traded on public markets as part of announced stock repurchase programs. The repurchased common stock is classified as treasury stock on the consolidated balance sheets and held at cost. As of December 31, 2022 and September 30, 2022, the Company did not hold any treasury stock.

Preferred Stock

Our certificate of incorporation authorizes the issuance of "blank check" preferred stock with designations, rights and preferences as may be determined from time to time by our board of directors up to an aggregate of 5,000,000 shares of preferred stock. As of December 31, 2022 and September 30, 2022, the Company has not issued any preferred stock.

Interest Rate Swap

The Company uses derivative financial instruments to manage interest rate risk associated with its variable debt. The Company's objective in using these interest rate derivatives is to manage its exposure to interest rate movements and reduce volatility of interest expense. The gains and losses due to changes in the fair value of the interest rate swap agreements completely offset changes in the fair value of the hedged portion of the underlying debt. Offsetting changes in fair value of both the interest rate swaps and the hedged portion of the underlying debt are recognized in interest expense in the consolidated statements of operations. The Company does not hold or issue any derivative instruments for trading or speculative purposes.

Risks & Uncertainties

Management evaluates the impact of global markets and economic factors on our industry and the potential for adverse effects on the Company's consolidated financial position and its operations. As of the date of these consolidated financial statements, there was no indication of any global or economic impacts to our industry.

3. New Accounting Pronouncements

In March 2020 and January 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” and ASU No. 2021-01, “Reference Rate Reform (Topic 848): Scope,” respectively (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In December 2022, FASB issued ASU 2022-06 "Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848" which defers the end date for electing the relief provided in Topic 848 from December 31, 2022 to December 31, 2024. In the first quarter of fiscal 2023, the Company adopted the optional expedients and exceptions provided in Topic 848. The adoption did not have a material impact on the Company’s consolidated financial statements.


4. Business Combinations

Acquisition of Grove Resource Solutions, LLC

On December 8, 2022, the Company acquired 100% of the equity interests of Grove Resource Solution, LLC ("GRSi") for a net preliminary purchase price of $185.1 million, inclusive of the preliminary working capital adjustment. The acquisition was financed through a combination of:

borrowings of $178.1 million under the Company’s amended and restated credit facility; and
common stock issued of approximately 0.5 million shares, which were valued at $7.0 million in the aggregate, based on the 20-day volume-adjusted average price of its common stock.

The acquisition of GRSi was consistent with the Company’s growth strategy, as it provided contract diversification, addition of key capabilities and increased presence in the military health market. The estimated goodwill derived from this transaction is primarily due to these attributes.

We have used the acquisition method of accounting for this transaction, whereby the assets acquired and liabilities assumed are recognized based upon their estimated fair values at the acquisition date.
The preliminary purchase price for GRSi was $188.5 million adjusted to reflect acquired cash, assumed liabilities and preliminary net working capital adjustments.

The Purchase Agreement contains customary representations, warranties and covenants by the parties. Subject to certain limitations and conditions, the seller and the equity holders of the seller do not have indemnity obligation for damages resulting from breaches or inaccuracies of the representations, warranties, and covenants of the seller, GRSI and the equity holders as set forth in the Purchase Agreement. The Purchase Agreement also provided for the establishment of an escrow account in order to satisfy (i) any downward adjustment of the purchase price base on GRSI's net working capital at the closing and (ii) certain specified indemnification obligations of the seller and equity holders that may arise following the closing. The escrow account is funded by an aggregate amount of approximately $4.3 million and the stock consideration. A representations and warranties insurance policy has been purchased by the Company in connection with the Purchase Agreement, under which the Company may seek recourse for breaches of the representations and warranties of the seller, GRSI and the equity holders. The representations and warranties insurance policy is subject to certain customary exclusions and a deductible.

In accordance with ASU 2017-01, the Company evaluated the transaction as an acquisition of a business. We are still assessing the acquisition price to the fair value of the assets and liabilities of GRSi at the acquisition date. We are awaiting the fair values of the intangibles assets from the third party valuation firm. The preliminary purchase price and its allocation are shown below and are subject to change once the valuation is complete. Based on the unaudited financial statements of GRSi on December 8, 2022, we accounted for the total acquisition consideration and allocation of fair value to the related assets and liabilities on a preliminary basis as follows (in thousands):
Preliminary purchase price for GRSi$188,458 
Purchase price allocation:
Accounts receivable 25,468 
Other current assets1,354 
Accounts payable and accrued expenses(2,449)
Payroll liabilities(7,827)
Other current liabilities(325)
Equipment and improvements, net 463 
Other long-term assets and liabilities (611)
Intangible assets98,004 
Total identifiable net assets acquired114,824 


All operating units are aggregated into a single reportable segment. The acquisition of GRSi did not create an additional reportable segment as all operations report to a single Chief Operating Decision Maker (CODM), serve a similar customer base, and provide similar services within a common regulatory environment. The goodwill represents intellectual capital and the acquired workforce, of which both do not qualify as a separate intangible asset. The tax deductible goodwill is in the process of being calculated.

During the three months ended December 31, 2022 following the completion of the acquisition, GRSi contributed approximately $6.9 million of revenue and $0.3 million of income from operations.
The following table presents certain results for the three months ended December 31, 2022 and 2021 as though the acquisition of GRSi had occurred on October 1, 2021. The unaudited pro forma information is presented for informational purposes only and is not necessarily indicative of our results if the acquisition had taken place on that date. The pro forma information was prepared by combining our reported historical results with the historical results of GRSi for the pre-acquisition periods. In addition, the reported historical amounts were adjusted for the following items, net of associated tax effects:

The impact of recording GRSi's intangible asset amortization.
The impact of interest expense for the new credit facility.
The removal of legacy GRSi director's fees.
The removal of transaction costs for the acquisition incurred by GRSi.
(in thousands)
Three Months Ended
 December 31,
Pro forma results20222021
Revenue$99,823 $178,854 
Net income (loss)$2,181 $6,857 
Number of shares outstanding - basic13,306 12,749 
Number of shares outstanding - diluted14,276 14,295 
Basic earnings per share (loss)$0.16$0.54
Diluted earnings per share (loss)$0.15$0.48

5. Revenue Recognition
The following table summarizes the contract balances recognized on the Company's consolidated balance sheets as follows (in thousands):
December 31,September 30,
Contract assets$10,740 $7,682 
Contract liabilities$509 $ 

Disaggregation of Revenue from Contracts with Customers

We disaggregate our revenue from contracts with customers by customer, contract type, as well as whether the Company acts as prime contractor or subcontractor. We believe these categories best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following series of tables present our revenue disaggregated by these categories:


Revenue by customer for the three months ended December 31, 2022 and 2021 as follows (in thousands):
Department of Veterans Affairs$33,708 $28,193 
Department of Health and Human Services27,305 23,126 
Department of Defense10,263 8,495 
Department of Homeland Security167 91,328 
Other1,295 1,659 
Total $72,738 $152,801 

Revenue by contract type for the three months ended December 31, 2022 and 2021 as follows (in thousands):
Time and Materials$48,991 $132,540 
Cost Reimbursable12,580 10,110 
Firm Fixed Price11,167 10,151 
Total $72,738 $152,801 

Revenue by whether the Company acts as a prime contractor or a subcontractor for the three months ended December 31, 2022 and 2021 as follows (in thousands):
Prime Contractor$67,981 $146,107 
Subcontractor4,757 6,694 
Total $72,738 $152,801 

6. Leases

The following table summarizes lease balances presented on our consolidated balance sheets as follows (in thousands):
December 31,September 30,
Operating lease right-of-use assets$19,595 $16,851 
Operating lease liabilities, current$3,379 $2,235 
Operating lease liabilities - long-term18,221 16,461 
     Total operating lease liabilities$21,600 $18,696 

As of December 31, 2022, operating leases for facilities and equipment have remaining lease terms of 0.1 to 8.3 years.

For the three months ended December 31, 2022 and 2021, total lease costs for our operating leases as follows (in thousands):
Operating $947 $952 
Short-term 43 27 
Variable 31 18 
Sublease income (a)(71)(69)
       Total lease costs$950 $928 

(a) The Company subleases a portion of one of its leased facilities. The sublease is classified as an operating lease with respect to the underlying asset. The sublease term is 5 years and includes two additional 1-year term extension options.

The Company's future minimum lease payments as of December 31, 2022 as follows (in thousands):
For the Fiscal Year Ending September 30,
2023 (remaining)$3,455 
Total future lease payments26,658 
   Less: imputed interest(5,058)
Present value of future minimum lease payments21,600 
   Less: current portion of operating lease liabilities(3,379)
Long-term operating lease liabilities$18,221 

At December 31, 2022, the weighted-average remaining lease term and weighted-average discount rate are 6.6 years and 6.38%, respectively. The calculation of the weighted-average discount rate was determined based on borrowing terms from our secured term loan.

Other information related to our leases for the three months ended December 31, 2022 and 2021 as follows (in thousands):

Cash paid for amounts included in the measurement of lease liabilities$1,022 $905 
Lease liabilities arising from obtaining right-of-use assets$3,541 $ 

7. Supporting Financial Information

Accounts receivable

The following table summarizes accounts receivable presented on our consolidated balance sheets as follows (in thousands):

December 31,September 30,
Billed receivables$54,438 $32,814 
Contract assets10,740 7,682 
Allowance for doubtful accounts  
Accounts receivable$65,178 $40,496 


Other current assets

The following table summarizes other current assets presented on our consolidated balance sheets as follows (in thousands):

December 31,September 30,
Prepaid insurance and benefits$601 $737 
Other receivables922 945 
Prepaid licenses and other expenses1,726 1,196 
Other current assets$3,249 $2,878 

Equipment and improvements, net

The following table summarizes equipment and improvements, net presented on our consolidated balance sheets as follows (in thousands):

December 31,September 30,
Furniture and equipment$893 $893 
Computer equipment2,730 2,316 
Computer software4,407 4,407 
Leasehold improvements1,614 1,614 
Total equipment and improvements9,644 9,230 
Less: accumulated depreciation and amortization(7,769)(7,526)
Equipment and improvements, net$1,875 $1,704 

Depreciation expense was $0.2 million and $0.3 million for the three months ended December 31, 2022 and 2021, respectively.

Intangible assets

The following table summarizes intangible assets, net presented on our consolidated balance sheets as follows (in thousands):

December 31,September 30,
Intangible assets
Customer contracts and related customer relationships$150,187 $62,281 
Covenants not to compete637 522 
Trade name13,034 3,051 
Total intangible assets163,858 65,854 
Less: accumulated amortization
Customer contracts and related customer relationships(25,622)(23,606)
Covenants not to compete(330)(316)
Trade name(1,177)(1,048)
Total accumulated amortization(27,129)(24,970)
Intangible assets, net$136,729 $40,884 

Amortization expense was $2.2 million and $1.6 million for the three months ended December 31, 2022 and 2021.


As of December 31, 2022, the estimated amortization expense per fiscal year as follows (in thousands):

2023 (remaining)$12,218 
Total amortization expense$136,729 


The change in the carrying amount of goodwill for the three months ended December 31, 2022 as follows (in thousands):

Balance at September 30, 2022$65,643 
Preliminary increase from GRSi acquisition (a)73,634 
Balance at December 31, 2022$139,277 

Ref (a) The Company is currently assessing the valuation of the GRSi acquisition to make the final purchase price adjustments which may impact the final carrying value of Goodwill. The balance provided is an estimate and subject to revision. Please refer to Note 4 for more information.

Accounts payable and accrued liabilities

The following table summarizes accounts payable and accrued liabilities presented on our consolidated balance sheets as follows (in thousands):

December 31,September 30,
Accounts payable$16,489 $11,886 
Accrued benefits (a)3,108 3,857 
Accrued bonus and incentive compensation916 3,625 
Accrued workers' compensation insurance2,795 4,880 
Accrued fringe (b)1,099 775 
Accrued interest payable1,088  
Accrued purchase price adjustment3,379  
Other accrued expenses3,837 1,839 
Accounts payable and accrued liabilities$32,711 $26,862 

(a) Includes employee insurance plans and other related benefits.
(b) Includes the 401(k) plan and other fringe benefits.


Debt obligations

The following table summarizes debt obligations presented on our consolidated balance sheets as follows (in thousands):

December 31,September 30,
Secured revolving line of credit$16,939 $ 
Secured term loan186,438 22,000 
Less: unamortized deferred financing costs(8,930)(1,584)
Net bank debt obligations194,447 20,416 
Less: current portion of debt obligations, net of deferred financing costs(28,505) 
Long-term portion of debt obligations, net of deferred financing costs$165,942 $20,416 

Interest expense

The following table summarizes interest expense presented on our consolidated statements of operations for the three months ended December 31, 2022 and 2021 as follows (in thousands):

Interest expense (a)$1,554 $521 
Amortization of deferred financing costs (b)276 151 
Interest expense$1,830 $672 

(a) Interest expense on borrowing.
(b) Amortization of expenses related to secured term loan and secured revolving line of credit.

8. Credit Facilities

A summary of our credit facilities as of December 31, 2022 and September 30, 2022 as follows (in millions):
December 31, 2022September 30, 2022
ArrangementLoan BalanceInterestArrangementLoan BalanceInterest
Secured term loan (a) due December 8, 2027$186.4 SOFR* + 4.2%Secured term loan due September 30, 2025$22.0 LIBOR + 2.5%
Secured revolving line of credit (b) due December 8, 2027$16.9 SOFR* + 4.2%Secured Revolving line of Credit due September 20, 2025$— LIBOR + 2.5%

*Secured Overnight Financing Rate ("SOFR") as of December 31, 2022 was 4.23%.
(a) Represents the principal amounts payable on our term loan, which is secured by liens on substantially all of the assets of the Company. The principal of the term loan is payable in quarterly installments with the remaining balance due on December 8, 2027.

The Credit Agreement requires compliance with a number of financial covenants and contains restrictions on our ability to engage in certain transactions. Among other matters, we must comply with limitations on the following: granting liens; incurring other indebtedness; maintenance of assets; investments in other entities and extensions of credit; mergers and consolidations; and changes in nature of business. The loan agreement also requires us to comply with certain quarterly financial covenants including: (i) a minimum fixed charge coverage ratio of at least 1.25 to 1.00, and (ii) a total leverage ratio not exceeding the ratio of 4.50:1.0 to 2.00:1.0 through maturity. The total leverage ratio is calculated by dividing the Company's total interest-bearing debt by net income adjusted to exclude (i) interest and

other expenses, (ii) provision for or benefit from income taxes, if any, (iii) depreciation and amortization, and (iv) non-cash charges, losses or expenses, including stock-based compensation, and (v) non-recurring charges, losses or expenses to include transaction and non-cash equity expense. We are in compliance with all loan covenants and restrictions.

We are required to pay quarterly amortization payments, which commenced in December 2022. The annual amortization amounts are $14.25 million each for fiscal years 2023 and 2024, $19.0 million each for fiscal years 2025 and 2026, and $23.75 million for fiscal year 2027, with the remaining unpaid loan balance due at maturity in December 2027. The quarterly payments are equal installments. The Company made a mandatory prepayment of $3.6 million during the quarter ended December 31, 2022 bringing the outstanding principal balance on the secured term loan to $186.4 million. We have satisfied mandatory principal amortization until March 31, 2023.

In addition to quarterly payments of the outstanding indebtedness, the loan agreement also requires annual payments of a percentage of excess cash flow, as defined in the loan agreement. The loan agreement states that an excess cash flow recapture payment must be made equal to (a) 75% of the excess cash flow for the immediately preceding fiscal year in which the total leverage ratio is greater than or equal to 2.50:1.0; (b) 50% of the excess cash flow for the immediately preceding fiscal year in which the total leverage ratio is less than 2.50:1.0 but greater than or equal to 1.5:1.0; or (c) 0% of the excess cash flow for the immediately preceding fiscal year in which the total leverage ratio is less than 1.5:1.0. In addition, the Company must make additional mandatory prepayment of amounts outstanding based on proceeds received from asset sales and sales of certain indebtedness. For additional information regarding the schedule of future payment obligations, please refer to Note 11. Commitments and Contingencies.

On September 30, 2019, we executed a floating-to-fixed interest rate swap with First National Bank ("FNB") as counter-party. The notional amount in the floating-to-fixed interest rate swap as of December 31, 2022 is $16.2 million and matures in 2024. The remaining outstanding balance of our term loan is subject to interest rate fluctuations. On the notional amount, the Company pays a base fixed rate of 1.61%, plus applicable credit spread. As a result, for the three months ended December 31, 2022, interest expense has been decreased by approximately $0.1 million.

(b) The secured revolving line of credit has a ceiling of up to $70.0 million; as of December 31, 2022 we had unused borrowing capacity of $31.2 million, which is net of outstanding letters of credit. Borrowing on the line of credit is secured by liens on substantially all of the assets of the Company. The Company accessed funds from the revolving credit facility during the quarter, but had an outstanding balance at December 31, 2022 of $16.9 million.
The Company's total borrowing availability, based on eligible accounts receivable at December 31, 2022, was $70.0 million. As part of the revolving credit facility, the lenders agreed to a sublimit of $5 million for letters of credit for the account of the Company, subject to applicable procedures.

The revolving line of credit has a maturity date of December 8, 2027 and is subject to loan covenants as described above. The Company is fully compliant with those covenants.

9. Stock-Based Compensation and Equity Grants

Stock-based compensation expense
Options issued under equity incentive plans were designated as either incentive stock or non-statutory stock options. No option is granted with a term of more than 10 years from the date of grant. Exercisability of option awards may depend on achievement of certain performance measures determined by the Compensation Committee of our Board. Shares issued upon option exercise are newly issued shares. As of December 31, 2022, there were 1.4 million shares available for grant under the 2016 Omnibus Equity Incentive Plan.


Stock-based compensation expense, shown in the table below, is recorded in general and administrative expenses included in our consolidated statements of operations for the three months ended December 31, 2022 and 2021 as follows (in thousands):

DLH employees (a)$372 $338 
Non-employee directors (b)180 162 
Total stock option expense$552 $500 

(a) Included in this amount are equity grants of restricted stock units to Executive Officers, which were issued in accordance with the DLH long-term incentive compensation policy in this fiscal year, and stock option grants to executive officers and non-executive company employees. The restricted stock units totaled 140,404 and 147,431 restricted stock units issued and outstanding at December 31, 2022 and 2021, respectively.

(b) Equity grants of restricted stock units were made in accordance with DLH compensation policy for non-employee directors and a total of 58,517 and 53,510 restricted stock units were issued and outstanding at December 31, 2022 and 2021, respectively.

Unrecognized stock-based compensation expense

Unrecognized stock-based compensation expense is presented in the table below for the three months ended December 31, 2022 and 2021 as follows (in thousands):
Unrecognized expense for DLH employees (a)$4,750 $5,592 
Unrecognized expense for non-employee directors538 486 
Total unrecognized expense$5,288 $6,078 

(a) On a weighted average basis, the unrecognized expense for the three months ended December 31, 2022 is expected to be recognized within the next 3.70 years.

Stock option activity for the three months ended December 31, 2022

The aggregate intrinsic value in the table below represents the total pretax intrinsic value (i.e., the difference between the Company’s closing stock price on the last trading day of the period and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their in the money options on those dates. This amount will change based on the fair market value of the Company’s stock.
(in years)
WeightedAverage(in thousands)
(in thousands)AverageRemainingAggregate
Number ofExerciseContractualIntrinsic
Options outstanding, September 30, 20222,392 $7.05 5.40$13,566 
Exercised(250)0.95 — — 
Cancelled(25)8.96 — — 
Options outstanding, December 31, 20222,117 $7.74 5.78$9,913 


Stock options shares outstanding, vested and unvested for the periods ended as follows (shares in thousands):

December 31,September 30,
Vested and exercisable (a)1,892 2,117 
Unvested (b)225 275 
Options outstanding2,117 2,392 

(a) The weighted average exercise price of vested and exercisable shares was $6.74 and $5.86 at December 31, 2022 and September 30, 2022, respectively. Aggregate intrinsic value was approximately $9.9 million and $13.6 million at December 31, 2022 and September 30, 2022, respectively. The weighted average contractual term remaining was 5.4 years and 4.9 years at December 31, 2022 and September 30, 2022, respectively.

(b) Certain awards vest upon satisfaction of certain performance criteria.

10. Earnings Per Share
Basic earnings per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding and restricted stock grants that vested or are likely to vest during the period. Diluted earnings per share is calculated by dividing income available to common shareholders by the weighted average number of basic common shares outstanding, adjusted to reflect potentially dilutive securities. Diluted earnings per share is calculated using the treasury stock method.

Earnings per share information is presented in the table below for the three months ended December 31, 2022 and 2021 as follows (in thousands except for per share amounts):
Net income$1,547 $7,804 
Denominator for basic net income per share - weighted-average outstanding shares13,306 12,749 
Effect of dilutive securities:
Stock options and restricted stock970 1,546 
Denominator for diluted net income per share - weighted-average outstanding shares14,276 14,295 
Net income per share - basic$0.12 $0.61 
Net income per share - diluted$0.11 $0.55 

11. Commitments and Contingencies

Contractual obligations as of December 31, 2022 as follows (in thousands):
  Payments Due Per Fiscal Year
Debt obligations$203,377 $18,544 $23,333 $19,000 $19,000 $23,750 $99,750 
Facility operating leases26,544 3,393 4,516 3,884 3,656 2,582 8,513 
Equipment operating leases114 62 52     
Total contractual obligations$230,035 $21,999 $27,901 $22,884 $22,656 $26,332 $108,263 


Workers' Compensation

We accrue workers' compensation expense based on claims submitted, applying actuarial loss development factors to estimate the costs incurred but not yet recorded. Our accrued liability for claims development as of December 31, 2022 and September 30, 2022 was $3.6 million and $4.9 million, respectively.

Legal Proceedings
As a commercial enterprise and employer, the Company is subject to various claims and legal actions in the ordinary course of business. These matters can include professional liability, workers’ compensation, tax, payroll and employee-related matters, other commercial disputes arising in the course of its business, and inquiries and investigations by governmental agencies regarding our employment practices or other matters. The Company is not aware of any pending or threatened litigation that it believes is reasonably likely to have a material adverse effect on its results of operations, financial position, or cash flows.

12. Related Party Transactions

The Company has determined that for the three months ended December 31, 2022 there were no significant related party transactions that have occurred which require disclosure through the date that these consolidated financial statements were issued.

Forward-Looking and Cautionary Statements
You should read the following discussion in conjunction with the Consolidated Financial Statements and the notes to those statements included elsewhere in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the year ended September 30, 2022, and in other reports we have subsequently filed with the SEC. This Quarterly Report on Form 10-Q contains certain statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Certain statements contained in this Management’s Discussion and Analysis are forward-looking statements that involve risks and uncertainties. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this report include, among others, statements regarding benefits of the acquisition, estimates of future revenues, operating income, earnings, earnings per share, backlog, and cash flows. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this report due to a variety of factors, including: the continuation of the novel coronavirus (“COVID-19”), including the measures to reduce its spread, and its impact on the economy and demand for our services, which are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the failure to achieve the anticipated benefits of our acquisition of GRSi or any future acquisition (including anticipated future financial operating performance and results); the diversion of management’s attention from normal daily operations of the business and the challenges of managing larger and more widespread operations resulting from our recent acquisition; the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our increased debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations of GRSi or any future acquisitions; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.

Business and Markets Overview

DLH enhances public health and national security readiness missions through science, technology, cyber, and engineering solutions and services. We are primarily focused on improving and better deploying large-scale federal health and human service initiatives. The Company derives 99% of its revenue from agencies of the Federal government, providing services to several agencies including the Department of Veteran Affairs ("VA"), Department of Health and Human Services ("HHS"), Department of Defense ("DoD"), and Department of Homeland Security, ("DHS"). The following table summarizes revenue by customer for the three months ended December 31, 2022 and 2021 as follows (in thousands and percent):

RevenuePercent of total revenueRevenuePercent of total revenue
Department of Veterans Affairs$33,708 46.4 %$28,193 18.5 %
Department of Health and Human Services27,305 37.5 %23,126 15.1 %
Department of Defense10,263 14.1 %8,495 5.6 %
Department of Homeland Security167 0.2 %91,328 59.8 %
Other customers with less than 10% share of total revenue1,295 1.8 %1,659 1.0 %
Total revenue$72,738 100.0 %$152,801 100.0 %

We provide solutions to three market focus areas: Defense and Veteran Health Solutions, Human Solutions and Services, and Public Health and Life Sciences. We deliver domain-specific expertise, industry best-practices and innovations to customers across these markets leveraging seven core competencies: secure data analytics, clinical trials and laboratory services, case management, performance evaluation, system modernization, operational logistics and readiness, and strategic digital communications. The Company manages its operations from its principal executive office in Atlanta, Georgia, and we have a complementary headquarters office in Silver Spring, Maryland. The Company employs over 3,200 skilled employees working throughout the United States and one location overseas.


On December 8, 2022, we acquired Grove Resource Solutions, LLC. ("GRSi") to increase future organic growth, diversify our customer base, and to expand into adjacent markets. GRSi provides research and development, systems engineering and integration, and digital transformations solutions to federal agencies, notably the National Institutes of Health ("NIH"), U.S. Navy and U.S. Marine Corp. For further information, refer to Note 4 of the accompanying notes to our consolidated financial statements contained elsewhere in this report.

Major Contracts

We operate primarily through prime contracts awarded by the government through competitive bidding processes. We have a diverse mix of contract vehicles with various agencies of the United State government, which supports our overall corporate growth strategy. Our Federal contract schedules are renewed on a recurring basis for multi-year periods.

The revenue attributable to the VA was derived from 16 separate contracts covering the Company's performance of pharmacy and logistics services in support of the VA's Consolidated Mail Outpatient Pharmacy ("CMOP") program.
Nine contracts for pharmacy services, which represent revenues of approximately $19.2 million and $15.6 million for the three months ended December 31, 2022 and 2021, respectively, are currently operating under a bridge contract through October 2023.
Seven contracts for logistics services, which represent approximately $14.5 million and $12.6 million of revenues for the three months ended December 31, 2022 and 2021, respectively, are currently operating under a bridge contract through November 2023.

The VA has issued a request for proposal for healthcare logistics and pharmacy services for each CMOP location. The procurement was set-aside for a service-disabled veteran owned small business ("SDVOSB") to be solicited as the prime contractor. DLH maintains relationships with SDVOSB partners. Should the new contracts for performance of these services be awarded to a partner of DLH, the Company expects to continue to perform a significant amount of the contract’s volume of business as a subcontractor. Should the VA conclude that an award to an SDVOSB prime contractor is not in the best interest

of the government, they may reissue a solicitation in an unrestricted competition. DLH believes that its service excellence over many years on the program would provide an advantage in an unrestricted competition.

The Company's contract with HHS in support of its Head Start program generated $9.1 million and $6.8 million of its revenue for the three months ended December 31, 2022 and 2021, respectively. This contract has a period of performance through April 2025.

We remain dependent upon the continuation of our relationships with the VA and HHS. Our results of operations, cash flows, and financial condition would be materially adversely affected if we were unable to continue our relationship with either of these customers, if we were to lose any of our material current contracts, or if the amount of services we provide to them was to be materially reduced.


At December 31, 2022, our backlog was approximately $942.7 million, of which $164.0 million was funded backlog. At September 30, 2022, our backlog was approximately $482.5 million, of which $98.9 million was funded backlog.

We define backlog as our estimate of remaining future revenue from existing signed contracts, assuming the exercise of all options relating to such contracts and including executed task orders issued under Indefinite Quantity/Indefinite Delivery ("IDIQ") contracts or if the contract is a single award IDIQ contract.

We define funded backlog as the portion of backlog for which funding is appropriated and allocated to the contract by the customer and authorized for payment by the customer, once specified work is completed. Funded backlog does not include the full contract value as Congress often appropriates funding for contracts on a yearly or quarterly basis.

Circumstances and events may cause changes in the amount of our backlog and funded backlog, including the execution of new contracts, extension of existing contracts, non-renewal or completion of current contracts, early termination, and adjustments to estimates. Changes in funded backlog may be affected by the funding cycles of the government. While no assurances can be given that existing contracts will result in earned revenue in any future period, or at all, our major customers have historically exercised their contractual renewal options.

Backlog value is quantified from management's judgment and assumptions about the volume of services based on past volume trends and current planning developed with customers.

Forward-Looking Business Trends

Our mission is to expand our position as a trusted provider of technology-enabled healthcare and public health services, medical logistics, and readiness enhancement services to active duty personnel, veterans, and civilian populations and communities. Our primary focus within the defense agency markets include military service members' and veterans' requirements for telehealth services, behavioral healthcare, medication therapy management, process management, clinical systems support, and healthcare delivery. Our primary focus within the civilian agency markets includes healthcare and social programs delivery and readiness. These include compliance monitoring on large scale programs, technology-enabled program management, consulting, and digital communications solutions ensuring that education, health, and social standards are being achieved within underserved and at-risk populations. We believe these business development priorities will position the Company to expand within top national priority programs and funded areas.


COVID-19 impact

We are exposed to and impacted by macroeconomic factors and U.S. government policies. Current general economic conditions, while improving, may continue to experience volatility due to the COVID-19 pandemic, which resulted in both market size contractions due to economic slowdowns and government restrictions on movement during the height of the pandemic. We are monitoring the evolving situation related to COVID-19, and we continue to work with our stakeholders to assess further possible implications to our business. We intend to continue with employee safety measures to ensure that we can continue our operations and take other actions where appropriate to mitigate other adverse consequences. Although we cannot currently predict the overall impact of COVID-19, the longer the duration of the event, the more likely it is that it could have an adverse effect on our business, financial position, results of operations, billable expenses, and/or cash flows. However, we have seen continued demand for the services we provide under our current contract portfolio as the services we provide are largely deemed essential. For the three months ended December 31, 2022, the COVID-19 pandemic did not have a material impact to revenues and operating income.

Further, due to our ability to continue to perform on our contract portfolio and generate cash flow, we do not presently expect nor have experienced liquidity constraints related to COVID-19. We are presently in compliance with all covenants in our secured term loan and have access to a secured revolving line of credit to meet any short-term cash needs that cannot be funded by operations. As such, mandatory demands on our cash flow remain low. Further, we have not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic.

Federal budget outlook for 2023

On December 29, 2022, the President signed into law the Consolidated Appropriations Act, 2023 to fund the Federal government for the remainder of the Federal government's 2023 fiscal year. Our customers' missions have received broad support from the legislative and executive branches of the Federal government. As such, we do not anticipate or expect any significant changes to our operations.

In addition, budget deficits and the growing U.S. national debt increase pressure on the U.S. government to reduce federal spending across all federal agencies. Presently, there is significant uncertainty about the size and timing of those reductions and the actions that Congress would pursue in order to resolve them. Current and future budget restrictions and other efforts to reduce U.S. government spending could cause clients to reduce or delay funding for orders for services or invest appropriated funds on a less consistent or rapid basis or not at all, particularly in light of current uncertainty around Congressional efforts to craft a long-term agreement on the U.S. government's ability to incur indebtedness in excess of its current limits.

Industry consolidation among federal government contractors

There has been active consolidation and a strong increase in merger and acquisition activity among federal government contractors over the past few years that we expect to continue, fueled by public companies leveraging strong balance sheets. Companies often look to acquisitions that augment core capabilities, contracts, customers, market differentiators, stability, cost synergies, and higher margin and revenue streams.

Potential impact of Federal Contractual set-aside Laws and Regulations:

The Federal government has an overall goal of 23% of prime contracts flowing through small businesses. As previously reported, various agencies within the federal government have policies that support small business goals, including the adoption of the “Rule of Two” by the VA, which provides that the agency shall award contracts by restricting competition for the contract to service-disabled or other veteran owned businesses. To restrict competition pursuant to this rule, the contracting officer must reasonably expect that at least two of these businesses, which are capable of delivering the services, will submit offers and that the award can be made at a fair and reasonable price that offers best value to the United States. When two qualifying small businesses cannot be identified, the VA may proceed to award contracts following a full and open bid process.

The Company believes that its past performance in this market and track record of success provide a competitive advantage. However, the effect of set-aside provisions may limit our ability to compete for prime contractor positions on programs that we recompete or that we have targeted for growth. In these cases, the Company may elect to join a team with an eligible contractor as prime in support of such small businesses for specific pursuits that align with our core markets and corporate growth strategy.


Results of Operations

For the Three Months Ended December 31, 2022 as Compared to the Three Months Ended December 31, 2021
The following table summarizes, for the periods indicated, consolidated statements of operations data expressed in dollars in thousands except for per share amounts, and as a percentage of revenue as follows (in thousands and percent):
 Three Months Ended
Consolidated Statements of Operations:December 31, 2022December 31, 2021Change
Revenue$72,738 100.0 %$152,801 100.0 %$(80,063)
Cost of operations:
Contract costs57,256 78.7 %132,686